The contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
12 07 2022
Historique:
received: 29 07 2021
accepted: 07 04 2022
pubmed: 28 4 2022
medline: 14 7 2022
entrez: 27 4 2022
Statut: ppublish

Résumé

Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic nonmalignant lymphadenopathy, splenomegaly, cytopenias, and other autoimmune manifestations. ALPS is caused by lymphocyte accumulation from defects in FAS-mediated apoptosis. Heterozygous germline or somatic pathogenic single nucleotide variants in FAS are the most common molecular etiology of ALPS. Through the Centralized Sequencing Program at the National Institute of Allergy and Infectious Diseases, we performed exome sequencing on subjects with a clinical diagnosis of ALPS, with a subset receiving copy number variant (CNV) analysis. In this cohort, we identified 3 subjects from unrelated families with CNVs at the FAS locus. One subject had a de novo ∼0.828 Mb copy number loss encompassing all of FAS. The second subject had a maternally inherited ∼1.004 Mb copy number loss encompassing all of FAS. The third subject had a paternally inherited ∼0.044 Mb copy number loss encompassing exons 7 through 9 of FAS. Subjects with deletions in FAS had clinical presentations and biomarker profiles similar to those with ALPS and with germline and somatic FAS variants. We demonstrate that CNV analysis should be pursued if there is clinical and biomarker evidence of ALPS because it can lead to a molecular diagnosis and appropriate treatment when FAS sequencing is inconclusive.

Identifiants

pubmed: 35476126
pii: 485071
doi: 10.1182/bloodadvances.2021005835
pmc: PMC9278309
doi:

Substances chimiques

fas Receptor 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3974-3978

Subventions

Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States

Informations de copyright

Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Int Immunol. 1998 Feb;10(2):195-202
pubmed: 9533447
Br J Haematol. 1998 Jul;102(2):578-81
pubmed: 9695976
Genet Med. 2012 Jan;14(1):81-9
pubmed: 22237435
Science. 1995 Jun 2;268(5215):1347-9
pubmed: 7539157
J Clin Invest. 2011 Jan;121(1):106-12
pubmed: 21183795
Hum Mutat. 2003 Jun;21(6):577-81
pubmed: 12754702
J Clin Immunol. 2018 Jul;38(5):558-568
pubmed: 29911256
Blood. 2010 Jun 24;115(25):5164-9
pubmed: 20360470
Lancet. 1996 Sep 14;348(9029):719-23
pubmed: 8806292
Blood. 2014 Mar 27;123(13):1989-99
pubmed: 24398331
J Immunol. 2011 May 15;186(10):6035-43
pubmed: 21490157
Am J Hum Genet. 1999 Apr;64(4):1002-14
pubmed: 10090885

Auteurs

Kathleen Jevtich (K)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Susan Price (S)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Morgan Similuk (M)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Elaine Kulm (E)

Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD.

Jia Yan (J)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Michael Setzer (M)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Leila Jamal (L)

NIH Clinical Center Department of Bioethics, National Institutes of Health, Bethesda, MD; and.

Luis M Franco (LM)

National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.

Rajarshi Ghosh (R)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Magdalena Walkiewicz (M)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

V Koneti Rao (VK)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH